You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》瑞信:藥明生物(02269.HK)股價波動 料市場對醫藥研發與生產外包業看法悲觀
阿思達克 11-08 14:35
瑞信發表研究報告指,醫藥合同外包服務(CXO)行業持續調整,但認為基本面依然穩固,繼續將藥明生物(02269.HK)列為行業首選之一。 近期CXO板塊受市場影響出現大幅調整,藥明生物股價波動相信主要是受短期市場悲觀情緒所影響,惟仍然相信中國CXO行業前景穩健,又指機構投資者將部分頭寸套現獲利屬正常現象,經過近期調整後行業一年遠期市盈率已回到更安全水平,支持龍頭企業上行。 該行又指出,美國藥企Charles River Laboratories第三季業已遜於市場預期,但並不能證明全球市場放緩,第三季醫療健康融資減少對龍頭企業亦沒有實質影響,維持對藥明的「跑贏大市」評級及目標價151元不變。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account